• 10 APR 2017
    • 0

    PharmaCyte Biotech’s Cannabis Research Program Sees Significant Progress in University of Northern Colorado Presentations

    LAGUNA HILLS, Calif., April 10, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado (UNC), has made significant progress with PharmaCyte’s Cannabis Research Program.

    Read more →
    • 03 APR 2017
    • 0

    PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development

    LAGUNA HILLS, Calif., April 03, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Mark L. Rabe, MD, as Director of Cannabis Program Development. In his new role, Dr. Rabe

    Read more →
    • 22 MAR 2017
    • 0

    PharmaCyte Biotech Strengthens Protection of Cancer Therapy with Patent Filing

    LAGUNA HILLS, Calif., March 22, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) to protect

    Read more →
    • 17 MAR 2017
    • 0

    PharmaCyte Biotech CEO Addresses IND Submission Questions

    LAGUNA HILLS, Calif., March 17, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today released a statement by Chief Executive Officer Kenneth L. Waggoner that addresses the company’s position on releasing a date for

    Read more →
    • 13 MAR 2017
    • 0

    PharmaCyte Biotech Names Dr. Leonard Makowka as Senior Strategic Advisor

    LAGUNA HILLS, Calif., March 13, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has named Leonard Makowka, M.D., Ph.D. as Senior Strategic Advisor to the Chief Executive Officer and Board

    Read more →
    • 21 FEB 2017
    • 0

    PharmaCyte Biotech Discusses Patient Enrollment and TD2’s Role in Upcoming Clinical Trial

    LAGUNA HILLS, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the third article in a series of Q&A articles that will be conducted with some of the key team

    Read more →
    • 13 FEB 2017
    • 0

    PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity

    LAGUNA HILLS, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today discussed the comparator arm for its upcoming clinical trial and provided additional clarification on its recent pre-IND meeting with the

    Read more →
    • 08 FEB 2017
    • 0

    PharmaCyte Biotech Releases Shareholder Call and Complete Q&A Playback Information

    LAGUNA HILLS, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that an audio recording of the company’s shareholder call, which was held on February 7, 2017, by the Chief Executive

    Read more →
    • 02 FEB 2017
    • 0

    PharmaCyte Biotech Provides Update for February 7th Shareholder Call

    LAGUNA HILLS, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that during its upcoming shareholder call PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, will update shareholders on PharmaCyte’s clinical trial

    Read more →
    • 30 JAN 2017
    • 0

    PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA

    LAGUNA HILLS, Calif., Jan. 30, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, officially announced today that PharmaCyte has retained Facet Life Sciences, Inc. (Facet) to guide PharmaCyte through its pancreatic cancer therapy development

    Read more →